Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China

Xiaojie Huang, Liumei Xu, Lijun Sun, Guiju Gao, Weiping Cai, Yanfen Liu, Haibo Ding, Hongxia Wei, Ping Ma, Min Wang, Shuiqing Liu, Yaokai Chen, Xiaohong Chen, Qingxia Zhao, Jianhua Yu, Yuxia Song, Hui Chen, Hao Wu, Shanfang Qin, Linghua LiFrontiers in Pharmacology 2019 · DOI

TL;DR

This study provides the first large-scale, real-world evidence on the long-term efficacy and safety of lopinavir/ritonavir (LPV/r) as a second-line treatment for HIV in China. The findings demonstrate that LPV/r is effective in improving immune function and achieving viral suppression in patients who have failed first-line therapy, with generally tolerable side effects.

What Problem Does This Paper Address?

Antiretroviral therapy (ART) has significantly improved the lives of people living with HIV (PLWH). However, a growing number of individuals experience treatment failure with their initial ART regimen, necessitating a switch to second-line therapy. While guidelines from organizations like the World Health Organization (WHO) recommend protease inhibitors, specifically lopinavir/ritonavir (LPV/r), as a second-line option for middle- and low-income countries, there has been a lack of robust real-world data on its long-term effectiveness and safety in these settings. This study aims to fill that gap by evaluating LPV/r-based second-line ART in a large cohort of Chinese patients who have failed their first-line treatment.

Methods

This was a retrospective, multi-center cohort study conducted across 17 clinics in China from 2009 to 2016. The researchers analyzed data from a national database, supplemented with information from participants' medical records for adverse event details.

  • Participant Selection: The study included 1196 adult HIV patients who had failed their first-line ART regimen (defined by viral load ≥ 400 copies/mL at week 48, non-completion at week 48, or switching ART before week 48 due to side effects) and subsequently started LPV/r-based second-line ART.
  • Efficacy Assessment: Treatment effectiveness was measured by:
  • CD4+ T-cell recovery: Defined as reaching a CD4+ T-cell count > 500 cells/mm³.
  • Viral suppression: Defined as achieving a viral load < 400 copies/mL or < 50 copies/mL, depending on the method used during treatment.
  • Safety Assessment: Safety was evaluated by the rates of LPV/r-related adverse events (AEs), including lipid disorders, abnormal liver function, myelosuppression, and renal function.
  • Statistical Analysis: Standard descriptive statistics were used. Comparisons between groups were made using t-tests and chi-squared tests. Cox proportional-hazards models and logistic regression were employed to identify factors associated with immune recovery and WHO-defined stage IV disease.

Datasets

The study utilized a national database collected from 17 clinics across China between 2009 and 2016. This database contained demographic information, baseline CD4+ T-cell counts, viral load data, WHO clinical stage, ART treatment history, and HIV-related diseases. Adverse event data was collected separately from participants' medical records. No new benchmarks were introduced.

Key Insights and Ideas

  • Real-world validation of LPV/r: The study provides crucial real-world evidence supporting the WHO's recommendation of LPV/r as a second-line ART in resource-limited settings, moving beyond clinical trial data.
  • Significant immune recovery: LPV/r treatment led to a substantial increase in CD4+ T-cell counts over six years, indicating effective restoration of immune function.
  • High viral suppression rates: The majority of patients achieved and maintained viral suppression, a critical goal in HIV management, demonstrating the regimen's virological effectiveness.
  • Age and baseline CD4 matter for recovery: Younger age and higher baseline CD4+ T-cell counts were identified as key factors influencing better immune recovery, highlighting the importance of early intervention.
  • Lipid disorders are the main concern: While generally well-tolerated, LPV/r was associated with lipid disorders, which warrants careful monitoring, although no significant increase in LDL-C was observed.

Key Results

  • CD4+ T-cell Counts: Median CD4+ T-cell counts increased from 138 cells/mm³ at baseline to 475 cells/mm³ after six years of LPV/r treatment. 37.2% of participants achieved CD4 recovery (>500 cells/mm³).
  • Viral Suppression: At the end of the first year, viral suppression rates were high: 88.8% achieved < 400 copies/mL and 76.7% achieved < 50 copies/mL. These rates further increased to 95.8% (< 400 copies/mL) and 94.4% (< 50 copies/mL) by the end of the follow-up period.
  • Adverse Events: The most frequently reported AEs were LPV/r-induced lipid disorders. Rates of abnormal liver function, myelosuppression, and renal function were generally low. Notably, no significant increase in LDL-C was observed.
  • Factors Associated with CD4 Recovery: In multivariate analysis, baseline CD4+ T-cell count and age were significantly associated with CD4 recovery.
  • Factors Associated with Stage IV Disease: Baseline CD4+ T-cell count and viral load were the only significant factors associated with baseline WHO-defined stage IV disease.

Limitations and Future Work

  • Retrospective Design: The retrospective nature of the study means that data collection was not standardized for all variables, and there may be missing data for some baseline characteristics and outcomes, which could introduce bias.
  • AE Definition: The definition of an adverse event as "any abnormal finding during follow-up visit tests" might have led to an overestimation of AE prevalence.
  • Generalizability: While the study included participants from various regions in China, the findings might not be directly generalizable to all resource-limited settings globally due to differences in healthcare systems and patient populations.

The authors suggest that future research could focus on comparing LPV/r with other second-line regimens and further investigating the long-term impact of lipid disorders. They also emphasize the importance of integrating lipid profile monitoring into standard care for patients on LPV-containing regimens.

Summary updated

Abstract

The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain unknown. Therefore, we conducted a large-scale, multicenter retrospective cohort study to evaluate the efficacy and safety of LPV/r-based ART among HIV-infected adults in China in whom first-line therapy failed. The data were obtained from a national database covering 17 clinics in China for six years of follow-up from 2009 to 2016. Failure of first-line treatment was determined according to a viral load at least 400 copies/ml at week 48, non-completers at week 48 for any reason, and those who switched ART before week 48 for any reason such as side effects. Treatment effectiveness was assessed by the rate of CD4<sup>+</sup>T cell recovery, defined as >500 cells/mm<sup>3</sup>, and the proportion of patients achieving viral suppression, defined as <400 or <50 copies/ml according to the methods used during treatment. Safety was assessed by rates of LPV/r-related adverse events (AEs), including lipid disorder, severe abnormal liver function, myelosuppression, and renal function. Between 2009 and 2016, 1196 participants (median, 36 years old; IQR, 30-43 years) were ultimately enrolled. All patients had been on LPV/r-based second-line ART treatment for more than one year after failure of any first-line ART regimen. Overall CD4<sup>+</sup>T cell counts increased from 138 cells/mm<sup>3</sup> to 475 cells/mm<sup>3</sup> and 37.2% of all participants reached CD4 recovery. Viral suppression rates dramatically increased at the end of the first year (<400 copies/ml, 88.8%; <50 copies/ml, 76.7%) and gradually increased during follow-up (<400 copies/ml, 95.8%; <50 copies/ml, 94.4%). The most frequently reported AEs were LPV/r-induced lipid disorders with no obvious increase on LDL-C at follow-up visits. This is the first real-world LPV/r-based second-line treatment study to cover such a large population in China. These results provide strong clinical evidence that LPV/r-based second-line ART is effective in increasing CD4<sup>+</sup>T cell counts and viral suppression rates with tolerable side effects in HIV-infected adults in China in whom first-line treatment had failed.
BibTeX
@inproceedings{huang2019six,
  author = {Xiaojie Huang and Liumei Xu and Lijun Sun and Guiju Gao and Weiping Cai and Yanfen Liu and Haibo Ding and Hongxia Wei and Ping Ma and Min Wang and Shuiqing Liu and Yaokai Chen and Xiaohong Chen and Qingxia Zhao and Jianhua Yu and Yuxia Song and Hui Chen and Hao Wu and Shanfang Qin and Linghua Li},
  title = {{Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China}},
  booktitle = {Frontiers in Pharmacology},
  year = {2019},
  doi = {10.3389/fphar.2019.01455},
}
Figure